UPMC Hillman Cancer Center

Laura Stabile, PhD

Laura Stabile
Research Associate Professor of Pharmacology & Chemical Biology


Contact Information

Contact Information

Hillman Cancer Center
5117 Centre Avene
Lab 2.7
Pittsburgh, PA 15232

Phone: 412-623-7821
Email: las22@pitt.edu
Fax: 412-623-7768

Administrative Assistant
Name: Carm Campbell
Phone: 412-623-7770
Email: campbellcm@upmc.edu
Fax: 412-623-7768

Research Keywords

Research Keywords

Hormones; estrogen; estrogen receptor; epidermal growth factor receptor; fibroblast growth factor receptor; hepatocyte growth factor; vascular endothelial growth factor; signal transduction; lung cancer; targeted cancer therapies

Research Summary

Research Summary

Dr. Stabile’s laboratory is focused on the role of growth factors and hormones in the development of non-small cell lung cancer. Estrogen receptor signaling has been shown to be important in inducing proliferation in lung tumor preclinical models as well as promoting aggressive disease in lung cancer patients. We have demonstrated both genomic and non-genomic effects of estrogen in the lung and have elucidated cross-talk between the estrogen signaling pathway and multiple growth factor pathways including epidermal growth factor receptor, fibroblast growth factor receptor, hepatocyte growth factor and vascular endothelial growth factor. These preclinical studies have led to clinical trials examining the effectiveness of the anti-estrogen fulvestrant combined with targeted therapies for advanced stage lung cancer. Current interests include: 1) examining the mechanistic link between inflammation and estrogen signaling in lung carcinogenesis; 2) identification of dietary factors that modify lung cancer risk; and 3) development of novel therapeutic and prevention strategies involving hormonal manipulation and/or anti-inflammatory therapies in select high-risk populations.

Selected Publications

Selected Publications

  • Song JY, Siegfried JM, Diergaarde B, Land SR, Bowser R, Stabile LP, Dacic S, Dhir R, Romkes M, Weissfeld JL. Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors. Cancer Epidemiology. 2013 Aug;37(4):518-22. PubMed Link
    Shared Resources Used: TARPS
  • Stabile LP, He G, Lui VWL, Henry C, Gubish CT, Joyce S, Quesnelle K, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res. 2013 Jan 15:19(2):380-92. PubMed Link
    Shared Resources Used: AF
  • Stabile LP, Rothstein ME, Cunningham DE, Land SR, Dacic S, Keohavong P, Siegfried JM. Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis. 2012 Nov;33(11):2181-9. PubMed Link
    Shared Resources Used: AF, TARPS
  • Siegfried JM, Gubish CT, Rothstein ME, Henry C, Stabile LP. Combining the multi-targeted tyrosine kinase inhibitor vandetanib with the anti-estrogen fulvestrant enhances its anti-tumor effect in non-small cell lung cancer. J Thoracic Oncol. 2012 Mar;7(3):485-95. PubMed Link
    Shared Resources Used: AF
  • Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res. 2011 Jul 1;17(13):4425-38. PubMed Link
    Shared Resources Used: AF
  • Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene. 2011; Aug 18;30(33):3625-35. PubMed Link
  • Stabile LP, Rothstein ME, Keohavong P, Lenzner D, Land SR, Gaither-Davis AL, Kim KJ, Kaminski N, Siegfried JM. Therapeutic targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice. Cancers. 2010; 2(4), 2153-70. PubMed Link
    Shared Resources Used: AF
  • Stabile LP, Dacic S, Land SR, Lenzner D, Dhir R, Aquafondata M, Landreneau RJ, Siegfried JM. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 2011; Jan 1;17(1):154-64. PubMed Link
    Shared Resources Used: BF, TARPS
  • Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Nichols M, Siegfried JM. Estrogen receptor beta subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Mol Bio Biochem. 2009; Aug; 116(1-2):102-9. PubMed Link
    Shared Resources Used: AF
  • Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff J, Dacic S, Hoang T, Dubey S, Marcotte SM, Siegfried JM. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer. 2009. Apr;64(1): 51-9. PubMed Link

See all pubs (Pubmed)

Collaborations

Collaborations

Current Internal Collaborators

Timothy Burns, MD, PhD
Assistant Professor of Medicine
Member - Lung Cancer Program (LCP)

Sanja Dacic, MD, PhD
Associate Professor of Pathology
Member - Lung Cancer Program (LCP)

Brenda Diergaarde, PhD
Associate Professor of Human Genetics
Member - Cancer Epidemiology and Prevention Program (CEPP)
Member - Lung Cancer Program (LCP)

Current External Collaborators

Pamela Hershberger, PhD
Associate Professor of Molecular Pharmacology and Therapeutics
Roswell Park Cancer Institute

Jill Siegfried, PhD
Professor of Pharmacology
University of Minnesota

Shared Resource Usage

Shared Resource Usage

  • Animal Facility
  • Biostatistics Facility
  • Cytometry Facility
  • In Vivo Imaging Facility
  • Tissue and Research Pathology Services

Affiliated Graduate Programs

Affiliated Graduate Programs

  • Molecular Pharmacology

Department Website









Last modified: 6/23/17